** Shares of drug developer ARS Pharmaceuticals SPRY.O rise 2.6% to $11.15 premarket
** Co said late on Wednesday the U.S. FDA approved the expanded use of nasal spray for severe allergic reactions in patients who weigh between 15 kg and 30 kg
** The spray, sold under the brand name neffy, will be dosed at 1 mg for the new patient population
** Neffy is designed to be given at the first sign of a severe allergic reaction, and has been previously approved for people above 30 kg at dose of 2 mg
** SPRY has risen 21.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。